- Daaweyn
- Markhaatiyada
- Neuroblastoma
- Buro adag
- Markhaatiyada
- TILS
- Daaweynta Unugyada NK
- Myasthenia Gravis (MG)
- Leukemia-da Lymphoblastic ee Ba'an (B-ALL)
- Lupus Erythematosus oo nidaamsan (SLE)
- Leukemia-da Lymphoblastic ee Ba'an (T-ALL)
- Lymphoma-ka aan Hodgkin ahayn (NHL)
- Myeloma badan (MM)
- Lymphom-ka Unugga B-B ee Kala-baxa
- Leukemia-da B-lymphocytic
- Myeloma
Nin go'aan adag qaatay oo ka soo jeeda Hindiya ayaa la daalaa dhacaya kansarka caloosha
Waxaa jira nin adkeysi badan oo lagu magacaabo Thirandas Shiva Prasad. Waa 32 jir, wuxuuna ka yimid Hindiya. Maxaan u iftiimineynaa go'aankiisa? Waa kan sheekadiisa cajiibka ah.
Thirandas waxaa laga helay kansarka caloosha sanadkii 2023, isagoo la ildaran xanuun caloosha ah waxaana la xaqiijiyay inuu yahay kansarka unugyada giraanta heerka hoose. Wuxuu maray kemoterabiga neoadjuvant oo leh nidaam FLOT ah, waxaana ku xigay qalliin ay ku jirto qalliinka caloosha ee hoose. Iyadoo ay jiraan daaweyn qalliinka kadib, kansarku wuxuu ku soo noqdey metastases oo ku dhaca miskaha, taasoo keentay dhibaatooyin sida hydronephrosis, nabarro, iyo xannibaadyo. Wuxuu u adkeystay faragelinno badan, oo ay ku jiraan dialysis, stenting, iyo chemo dheeraad ah oo lagu sameeyay nab-paclitaxel, nivolumab, irinotecan, iyo kuwa kale. Sannadkii 2025, baaritaannada PET-CT waxay muujiyeen horumar iyadoo ay sii kordhayaan nabarrada caloosha iyo ascites, taasoo ka dhigtay inuu u baahdo fursado cusub.
Isagoo raadinaya daryeel casri ah, Thirandas wuxuu u jeestay BIOOCUS. Kooxdayada khubarada ah waxay bixiyeen qiimeyn bilow ah oo bilaash ah, iyagoo dib u eegaya taariikhdiisa ballaaran waxayna ku talinayaan daaweynta unugyada CLDN18.2 CAR-T, oo loogu talagalay muujinta burooyinka. Ka dib markii la diyaariyey, daawada si habsami leh ayaa loogu sameeyay xarunteena horumarsan. Iyadoo ay jiraan caqabado hore sida qandho iyo caabuq suurtagal ah, kooxdayada takhasuska badan leh waxay si wax ku ool ah u maareeyeen calaamadaha iyadoo la adeegsanayo antibiyootiko iyo daryeel taageero ah, iyagoo hubinaya inaysan jirin CRS daran. Habraacyada sida dheecaanka caloosha iyo hagaajinta stent-ka waxaa si sax ah loola dhaqmay, taasoo keentay yareynta calaamadaha iyo natiijooyinka cudurka ee wanaagsan daaweynta ka dib.
BIOOCUS waxay ka soo horjeedaa adeeggeeda sare iyo alaabada cusub. Daaweynteena CAR-T, oo bartilmaameedsanaysa CLDN18.2, waxay bixisaa weerar bartilmaameedsan oo lagu qaado unugyada kansarka, badanaa waxay ku guulaysataa meelaha daaweynta caadiga ah ay ku guuldaraysato. Adeegyada bukaanku waxay ku fiican yihiin isku-dubaridka safarka caalamiga ah, bixinta xasaasiyadda dhaqanka, iyo bixinta dabagal dhammaystiran, dhammaantoodna iyada oo aan culays dheeraad ah lahayn. Thirandas waxay qaddarinaysaa shaqaalaha naxariista leh iyo hababka hufan ee khibrad cabsi leh u beddelay mid rajo leh.
Submit An Free Inquiry
Our medical team will make an evaluation for you, based on the information you provided. This procedure is free of charge.

